Slow Capital, Inc. Bio N Tech Se Transaction History

Slow Capital, Inc.

$645 Million
Q3 2024

A detailed history of Slow Capital, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Slow Capital, Inc. holds 51,680 shares of BNTX stock, worth $6.13 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares

51,680

Previous 51,080 1.17%

Holding current value

$6.13 Million

Previous $4.1 Million 49.56%

% of portfolio

0.95%

Previous 0.66%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$78.36 - $124.66 $47,016 - $74,796	600 Added 1.17%	51,680 $6.14 Million
Q2 2024 Jul 24, 2024	BUY	$80.36 - $102.87 $439,328 - $562,390	5,467 Added 11.99%	51,080 $4.1 Million
Q1 2024 Apr 17, 2024	BUY	$88.96 - $112.35 $1.43 Million - $1.81 Million	16,087 Added 54.48%	45,613 $4.21 Million
Q4 2023 Jan 30, 2024	BUY	$90.91 - $112.75 $364,730 - $452,353	4,012 Added 15.72%	29,526 $3.12 Million
Q3 2023 Oct 19, 2023	SELL	$98.5 - $125.08 $90,029 - $114,323	-914 Reduced 3.46%	25,514 $2.77 Million
Q2 2023 Aug 09, 2023	SELL	$102.58 - $129.66 $110,273 - $139,384	-1,075 Reduced 3.91%	26,428 $2.85 Million
Q1 2023 Apr 26, 2023	BUY	$122.57 - $153.67 $90,211 - $113,101	736 Added 2.75%	27,503 $3.43 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $660,247 - $1.04 Million	5,575 Added 26.31%	26,767 $4.02 Million
Q3 2022 Oct 27, 2022	SELL	$127.65 - $183.11 $32,933 - $47,242	-258 Reduced 1.2%	21,192 $2.86 Million
Q2 2022 Jul 28, 2022	BUY	$123.25 - $186.24 $114,129 - $172,458	926 Added 4.51%	21,450 $3.2 Million
Q1 2022 May 02, 2022	BUY	$126.25 - $231.85 $2.59 Million - $4.76 Million	20,524 New	20,524 $3.5 Million

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Slow Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Slow Capital, Inc. with notifications on news.

Account